|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
|
ES2293638T3
(es)
|
1994-03-25 |
2008-03-16 |
Isotechnika, Inc. |
Mejora de la eficacia de farmacos por deuteracion.
|
|
TW200418829A
(en)
*
|
2003-02-14 |
2004-10-01 |
Avanir Pharmaceutics |
Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
|
|
EP1613625A1
(en)
|
2003-03-14 |
2006-01-11 |
AstraZeneca AB |
Novel fused triazolones and the uses thereof
|
|
GB0420970D0
(en)
|
2004-09-21 |
2004-10-20 |
Smithkline Beecham Corp |
Novel triazoloquinoline compounds
|
|
AR064416A1
(es)
*
|
2006-12-21 |
2009-04-01 |
Cancer Rec Tech Ltd |
Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
|
|
WO2011075747A1
(en)
|
2009-12-18 |
2011-06-23 |
Glaxosmithkline Llc |
Therapeutic compounds
|
|
US10376504B2
(en)
*
|
2015-07-29 |
2019-08-13 |
Merck, Sharp & Dohme Corp. |
Substituted quinolinones as PDE9 inhibitors
|
|
CN111406050B
(zh)
*
|
2018-01-17 |
2023-02-03 |
厦门宝太生物科技股份有限公司 |
吲哚胺2,3-双加氧酶抑制剂及其用途
|
|
KR102767739B1
(ko)
|
2018-06-27 |
2025-02-12 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물
|
|
CN112585139B
(zh)
|
2018-06-27 |
2023-12-01 |
百时美施贵宝公司 |
用作t细胞激活剂的萘啶酮化合物
|
|
BR112021026687A2
(pt)
|
2019-07-04 |
2022-03-08 |
Lead Pharma Holding Bv |
Composto ou um sal farmaceuticamente aceitável do mesmo, uso do dito composto e medicamento
|
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
|
JP7629912B2
(ja)
|
2019-10-18 |
2025-02-14 |
リード ファーマ ホールディング ビー．ブイ． |
エストロゲン関連受容体アルファ（ＥＲＲα）モジュレーター
|
|
US20230064809A1
(en)
|
2019-11-28 |
2023-03-02 |
Bayer Aktiengesellschaft |
Substituted aminoquinolones as dgkalpha inhibitors for immune activation
|
|
CR20220236A
(es)
*
|
2019-11-28 |
2022-10-03 |
Bayer Pharma AG |
Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
|
|
US20230062100A1
(en)
|
2019-11-28 |
2023-03-02 |
Bayer Aktiengesellschaft |
Substituted aminoquinolones as dgkalpha inhibitors for immune activation
|
|
IL294085A
(en)
|
2019-12-19 |
2022-08-01 |
Bristol Myers Squibb Co |
Combinations of dgk inhibitors and checkpoint antagonists
|
|
BR112022012204A2
(pt)
*
|
2019-12-23 |
2022-09-13 |
Bristol Myers Squibb Co |
Compostos de heteroarila substituída úteis como ativadores de célula t
|
|
KR20220119456A
(ko)
|
2019-12-23 |
2022-08-29 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 치환된 퀴놀리노닐 피페라진 화합물
|
|
CA3162979A1
(en)
|
2019-12-23 |
2021-07-01 |
Upender Velaparthi |
Substituted piperazine derivatives useful as t cell activators
|
|
BR112022012179A2
(pt)
|
2019-12-23 |
2022-09-06 |
Bristol Myers Squibb Co |
Compostos de quinazolina substituída úteis como ativadores de célula t
|
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
|
IL294032A
(en)
|
2019-12-24 |
2022-08-01 |
Carna Biosciences Inc |
Compounds that regulate diacylglycerol kinase
|
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
|
WO2022133083A1
(en)
|
2020-12-16 |
2022-06-23 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP7686091B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
WO2023011456A1
(en)
|
2021-08-03 |
2023-02-09 |
Beigene, Ltd. |
Pyrazolopyridinone compounds
|
|
JP2025507915A
(ja)
|
2022-03-01 |
2025-03-21 |
インシリコ メディスン アイピー リミティド |
ジアシルグリセロールキナーゼ（ＤＧＫ）α阻害剤及びその使用
|
|
EP4486741A4
(en)
|
2022-03-01 |
2026-04-08 |
Insilico Medicine Ip Ltd |
Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses
|
|
WO2023165525A1
(en)
|
2022-03-01 |
2023-09-07 |
Insilico Medicine Ip Limited |
Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
|
|
WO2023165528A1
(en)
|
2022-03-01 |
2023-09-07 |
Insilico Medicine Ip Limited |
Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
|
|
US20250215014A1
(en)
|
2022-03-31 |
2025-07-03 |
InventisBio Co., Ltd. |
Kinase inhibitors, preparation methods and uses thereof
|
|
CN118974049A
(zh)
|
2022-03-31 |
2024-11-15 |
益方生物科技(上海)股份有限公司 |
激酶抑制剂，其制备方法和用途
|